1. Home
  2. EDN vs CRGX Comparison

EDN vs CRGX Comparison

Compare EDN & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDN
  • CRGX
  • Stock Information
  • Founded
  • EDN 1992
  • CRGX 2021
  • Country
  • EDN Argentina
  • CRGX United States
  • Employees
  • EDN N/A
  • CRGX N/A
  • Industry
  • EDN Electric Utilities: Central
  • CRGX
  • Sector
  • EDN Utilities
  • CRGX
  • Exchange
  • EDN Nasdaq
  • CRGX Nasdaq
  • Market Cap
  • EDN 1.0B
  • CRGX 964.5M
  • IPO Year
  • EDN 2007
  • CRGX 2023
  • Fundamental
  • Price
  • EDN $32.51
  • CRGX $21.27
  • Analyst Decision
  • EDN
  • CRGX Strong Buy
  • Analyst Count
  • EDN 0
  • CRGX 7
  • Target Price
  • EDN N/A
  • CRGX $30.33
  • AVG Volume (30 Days)
  • EDN 187.3K
  • CRGX 157.2K
  • Earning Date
  • EDN 11-12-2024
  • CRGX 11-21-2024
  • Dividend Yield
  • EDN N/A
  • CRGX N/A
  • EPS Growth
  • EDN N/A
  • CRGX N/A
  • EPS
  • EDN 0.28
  • CRGX N/A
  • Revenue
  • EDN $880,068,817.00
  • CRGX N/A
  • Revenue This Year
  • EDN $144.81
  • CRGX N/A
  • Revenue Next Year
  • EDN $81.78
  • CRGX N/A
  • P/E Ratio
  • EDN $6.88
  • CRGX N/A
  • Revenue Growth
  • EDN N/A
  • CRGX N/A
  • 52 Week Low
  • EDN $10.06
  • CRGX $13.14
  • 52 Week High
  • EDN $34.18
  • CRGX $33.92
  • Technical
  • Relative Strength Index (RSI)
  • EDN 87.78
  • CRGX 53.21
  • Support Level
  • EDN $22.64
  • CRGX $19.96
  • Resistance Level
  • EDN $28.55
  • CRGX $21.60
  • Average True Range (ATR)
  • EDN 1.63
  • CRGX 1.35
  • MACD
  • EDN 0.75
  • CRGX -0.09
  • Stochastic Oscillator
  • EDN 85.53
  • CRGX 62.72

About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)

Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Share on Social Networks: